SAN DIEGO, March 3, 2022 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that it has scheduled its fourth quarter and year-end 2021
financial results conference call and webcast on Thursday, March 10, 2022, after the U.S.
financial markets close.
![Regulus Therapeutics Inc. Logo Regulus Therapeutics Inc. Logo](https://mma.prnewswire.com/media/370141/regulus_logo_finalnew_Logo.jpg)
In connection with the earnings release, Regulus' management
team will host a live conference call and webcast at 5:00 PM
ET on Thursday, March 10, 2022, to discuss the Company's
financial results and provide a corporate update. To access the
call, please dial (877) 257-8599 (domestic) or (970) 315-0459
(international) and refer to conference ID 3786683. To access the
telephone replay of the call, dial (855) 859-2056 (domestic) or
(404) 537-3406 (international), conference ID 3786683. The webcast
and telephone replay will be archived on the Company's website at
www.regulusrx.com following the call.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a
biopharmaceutical company focused on the discovery and development
of innovative medicines targeting microRNAs. Regulus has leveraged
its oligonucleotide drug discovery and development expertise to
develop a pipeline complemented by a rich intellectual property
estate in the microRNA field. Regulus maintains its corporate
headquarters in San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's RGLS8429
program, including the potential sufficiency of the preclinical
data required to support clinical studies, the expected timing for
submitting an IND and initiating a Phase 1 clinical study, the
expected timing for reporting topline data, and the timing and
future occurrence of other preclinical and clinical activities.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "intends," "will,"
"goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and the risk additional
toxicology data may be negative. In addition, while Regulus expects
the COVID-19 pandemic to adversely affect its business operations
and financial results, the extent of the impact on Regulus' ability
to achieve its preclinical and clinical development objectives and
the value of and market for its common stock, will depend on future
developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the
pandemic, travel restrictions, quarantines, social distancing and
business closure requirements in the U.S. and in other countries,
and the effectiveness of actions taken globally to contain and
treat the disease. These and other risks are described in
additional detail in Regulus' filings with the Securities and
Exchange Commission, including under the "Risk Factors" heading of
Regulus most recently quarterly report on Form 10-Q. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Regulus undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-timing-for-fourth-quarter-and-year-end-2021-financial-results-webcast-and-conference-call-301493880.html
SOURCE Regulus Therapeutics Inc.